Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 20, 2026, 7:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 175 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Limited Stage Small Cell Lung Cancer Clear all
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

NCT05353257
View directory record Official record
Conditions
Limited-Stage Small Cell Lung Cancer
Interventions
HLX10, carboplatin/cisplatin-etoposide, Thoracic radiotherapy, Placebo, Prophylactic Cranial Irradiation (PCI)
Drug · Radiation
Lead sponsor
Shanghai Henlius Biotech
Industry
Eligibility
18 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
31
States / cities
Arcadia, California • Los Alamitos, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Jul 20, 2026, 7:13 PM EDT
Terminated Not applicable Interventional

Pulmonary Interstitial Lymphography in Early Stage Lung Cancer

NCT01188486
View directory record Official record
Conditions
Lung Cancer, Lung Cancer Non-Small Cell Cancer (NSCLC), Lung Cancer Small Cell Lung Cancer (SCLC), Mesothelioma
Interventions
Stereotactic Body Radiation Therapy (SBRT), Computed Tomography (CT), Cyberknife, Trilogy, True Beam, Iohexol, Iodixanol
Radiation · Device · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2018 · Synced Jul 20, 2026, 7:13 PM EDT
Recruiting Phase 2 Interventional

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

NCT05061550
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Durvalumab, Oleclumab, Monalizumab, Dato-DXd, AZD0171, Carboplatin, Cisplatin, Pemetrexed/Cisplatin, Pemetrexed/Carboplatin, Carboplatin/Paclitaxel, Volrustomig, Rilvegostomig
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 95 Years
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
24
States / cities
Little Rock, Arkansas • Los Angeles, California • Oakland, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jul 20, 2026, 7:13 PM EDT
Completed Phase 1 Interventional

Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer

NCT00068549
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Stage IB Cervical Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage IVA Cervical Cancer
Interventions
Gemcitabine Hydrochloride, Cisplatin, Radiation Therapy, Internal Radiation Therapy
Drug · Radiation
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 24, 2014 · Synced Jul 20, 2026, 7:13 PM EDT
Completed Phase 2 Interventional Results available

Brain Irradiation in Treating Patients With Limited-Stage Small Cell Lung Cancer

NCT00057746
View directory record Official record
Conditions
Lung Cancer
Interventions
Prophylactic cranial irradiation, 2.5 Gy fx, Prophylactic cranial irradiation, 2.0 Gy fx, Prophylactic cranial irradiation, 1.5 Gy fx
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
Up to 120 Years
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
217
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 160 more
Source: ClinicalTrials.gov public record
Updated May 24, 2016 · Synced Jul 20, 2026, 7:13 PM EDT
Completed Not applicable Interventional

Study to Evaluate NA-NOSE for Monitoring and Detecting Recurrence in Early Stage Lung Cancer

NCT01840150
View directory record Official record
Conditions
Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer
Interventions
breath test, laboratory biomarker analysis
Procedure · Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2023 · Synced Jul 20, 2026, 7:13 PM EDT
Recruiting Phase 2 Interventional

IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)

NCT05742607
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
IPH5201 + durvalumab + standard chemotherapy
Drug
Lead sponsor
Innate Pharma
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
St. Petersburg, Florida • Tampa, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 20, 2026, 7:13 PM EDT
Completed Phase 1 Interventional

S0004: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-stage Small Cell Lung Cancer

NCT00006487
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, etoposide, tirapazamine, radiation therapy
Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
87
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Jul 20, 2026, 7:13 PM EDT
Terminated Phase 2 Interventional

Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer

NCT06140407
View directory record Official record
Conditions
Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer, Stage II Lung Cancer, Stage III Lung Cancer
Interventions
Cisplatin, Carboplatin, Etoposide, Pembrolizumab, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging, Biospecimen Collection, Radiation Therapy
Drug · Biological · Procedure + 1 more
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Jul 20, 2026, 7:13 PM EDT
Not listed Not applicable Interventional

Stereotactic Body Radiation Therapy for Un-biopsied Early- Stage Non Small Cell Lung Cancer

NCT02950337
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Group 1: Peripherally Located Tumors, Group 2: Peripherally Located Chest Wall Adjacent Tumors, Group 3: Centrally Located Tumors
Radiation
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
2
States / cities
Hines, Illinois • Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Jul 20, 2026, 7:13 PM EDT
Completed Phase 3 Interventional

Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer

NCT00031785
View directory record Official record
Conditions
Anorexia, Cachexia, Lung Cancer
Interventions
megestrol acetate, radiation therapy
Drug · Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Jul 20, 2026, 7:13 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Breath Analysis in Early Stage Lung Cancer Using Infrared Spectroscopy

NCT04556435
View directory record Official record
Conditions
Lung Cancer, Non Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
Breathe BioMedical Inc
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Jul 20, 2026, 7:13 PM EDT
Not listed Phase 3 Interventional Results available

Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

NCT00632853
View directory record Official record
Conditions
Lung Cancer
Interventions
Standard Radiation Dose Therapy, cisplatin, etoposide, High Radiation Dose Therapy, carboplatin
Radiation · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
930
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 574 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2023 · Synced Jul 20, 2026, 7:13 PM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

NCT03794544
View directory record Official record
Conditions
Resectable, Early-stage, NSCLC
Interventions
Durvalumab, Oleclumab, Monalizumab, Danvatirsen
Drug · Combination Product
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 102 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
10
States / cities
La Jolla, California • Fort Myers, Florida • Leesburg, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Jul 20, 2026, 7:13 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

SBRT Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)

NCT03050554
View directory record Official record
Conditions
Early Stage Non-Small Cell Lung Cancer
Interventions
Avelumab, SBRT
Drug · Radiation
Lead sponsor
Andrew Sharabi
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
La Jolla, California • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Jul 20, 2026, 7:13 PM EDT
Terminated Phase 4 Interventional

Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC

NCT05583188
View directory record Official record
Conditions
NSCLC
Interventions
Aliya Pulsed Electric Fields (PEF) ablation, Nivolumab plus Platinum Doublet Chemotherapy, Standard of care neoadjuvant therapy, Surgical Resection
Device · Drug · Other
Lead sponsor
Galvanize Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Jul 20, 2026, 7:13 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identifying Biomarkers for Lung Cancer Using Tissue Samples From Patients With Lung Cancer and From Healthy Participants

NCT00899028
View directory record Official record
Conditions
Lung Cancer
Interventions
comparative genomic hybridization, fluorescence in situ hybridization, gene expression analysis, microarray analysis, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, matrix-assisted laser desorption/ionization time of flight mass spectrometry, medical chart review, diagnostic bronchoscopy
Genetic · Other · Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
689 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2016
U.S. locations
4
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Jul 20, 2026, 7:13 PM EDT
Completed Phase 1 Interventional

Photodynamic Therapy With HPPH in Treating Patients With Non-Small Cell Lung Cancer

NCT00025571
View directory record Official record
Conditions
Lung Cancer
Interventions
HPPH
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2011 · Synced Jul 20, 2026, 7:13 PM EDT
Completed Phase 3 Interventional

Topotecan in Treating Patients With Relapsed Small Cell Lung Cancer

NCT00003917
View directory record Official record
Conditions
Lung Cancer
Interventions
topotecan hydrochloride
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
53
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Jul 20, 2026, 7:13 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

NCT07128199
View directory record Official record
Conditions
NSCLC, Stage IB-IIIA, Lung Cancer, Adjuvant, Post-surgical, EGFR, Exon 20, Early Stage Lung Cancer, Uncommon EGFR Mutations
Interventions
Cisplatin, Carboplatin, Pemetrexed, TAS6417, Zipalertinib Matching-placebo
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
30
States / cities
Anchorage, Alaska • Duarte, California • Irvine, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 20, 2026, 7:13 PM EDT
Completed No phase listed Observational

Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer

NCT00897793
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer
Interventions
venipuncture, radiation therapy
Procedure · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Jul 20, 2026, 7:13 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Limited Stage or Extensive Stage Small Cell Lung Cancer

NCT02635009
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Carcinoma, Limited Stage Small Cell Lung Carcinoma
Interventions
Three-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy
Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
270
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 217 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 20, 2026, 7:13 PM EDT
Active, not recruiting Phase 3 Interventional

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

NCT02201992
View directory record Official record
Conditions
ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Interventions
Clinical Observation, Crizotinib, Laboratory Biomarker Analysis
Other · Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2036
U.S. locations
1613
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 978 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Jul 20, 2026, 7:13 PM EDT
Recruiting Phase 2 Interventional

MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer

NCT05903092
View directory record Official record
Conditions
Small Cell Lung Cancer, SCLC, Extensive Stage Small Cell Lung Cancer, Limited Stage Small-Cell Lung Cancer
Interventions
Durvalumab, Monalizumab, Carboplatin or Cisplatin, Etoposide
Drug
Lead sponsor
Hirva Mamdani
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
4
States / cities
Indianapolis, Indiana • Iowa City, Iowa • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jul 20, 2026, 7:13 PM EDT